BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8836391)

  • 1. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH deficiency.
    O'Halloran DJ; Wieringa G; Tsatsoulis A; Shalet SM
    Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():330-4. PubMed ID: 8836391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
    Esposito V; Di Biase S; Lettiero T; Labella D; Simeone R; Salerno M
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):607-11. PubMed ID: 15521964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.
    Colao A; di Somma C; Cuocolo A; Spinelli L; Tedesco N; Pivonello R; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 May; 86(5):1874-81. PubMed ID: 11344175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.
    O'Halloran DJ; Tsatsoulis A; Whitehouse RW; Holmes SJ; Adams JE; Shalet SM
    J Clin Endocrinol Metab; 1993 May; 76(5):1344-8. PubMed ID: 8496328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency.
    Elgzyri T; Castenfors J; Hägg E; Backman C; Thorén M; Bramnert M
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):113-22. PubMed ID: 15212653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor.
    Borges JL; Blizzard RM; Evans WS; Furlanetto R; Rogol AD; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1984 Jul; 59(1):1-6. PubMed ID: 6427267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents.
    Lanes R; Gunczler P; Lopez E; Esaa S; Villaroel O; Revel-Chion R
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1061-5. PubMed ID: 11238486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency.
    Garry P; Collins P; Devlin JG
    Eur J Endocrinol; 1996 Jan; 134(1):61-6. PubMed ID: 8590957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels.
    Leonsson M; Oscarsson J; Bosaeus I; Lundgren BK; Johannsson G; Wiklund O; Bengtsson BA
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1296-303. PubMed ID: 10199770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
    Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
    J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy.
    O'Neal DN; Hew FL; Best JD; Alford F
    Growth Horm IGF Res; 1999 Jun; 9(3):165-73. PubMed ID: 10502452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response.
    Svensson J; Finer N; Bouloux P; Bevan J; Jonsson B; Mattsson AF; Lundberg M; Harris PE; Koltowska-Häggström M; Monson JP;
    Growth Horm IGF Res; 2007 Feb; 17(1):67-76. PubMed ID: 17223598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance.
    Beshyah SA; Henderson A; Niththyananthan R; Skinner E; Anyaoku V; Richmond W; Sharp P; Johnston DG
    J Clin Endocrinol Metab; 1995 Feb; 80(2):356-63. PubMed ID: 7852490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the impact of recombinant human growth hormone (rhGH) on the plasma lipid profile beneficial or harmful?
    Querfeld U
    Br J Clin Pract Suppl; 1996 Aug; 85():54-5. PubMed ID: 8995033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study.
    Colao A; di Somma C; Pivonello R; Cuocolo A; Spinelli L; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1088-93. PubMed ID: 11889170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
    Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
    Bengtsson BA; Edén S; Lönn L; Kvist H; Stokland A; Lindstedt G; Bosaeus I; Tölli J; Sjöström L; Isaksson OG
    J Clin Endocrinol Metab; 1993 Feb; 76(2):309-17. PubMed ID: 8432773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.